June 6, 2015 - The next conference on Neurological Clinical Trials will be held in Milan the next June, 25. A focus on Huntington Disease will be presented by Prof Ferdinando Squitieri.
COVID-19 quickly disrupted customary clinical practices. Within few weeks, as quarantine and social distancing became the norm, in-person medical appointments became increasingly sporadic and were replaced by those conducted with audiovisual tools. In doing so, telemedicine, hitherto on the margins, became protagonist.
In an official statement of 17 November 2020, PTC Therapeutics announced the initiation of a Phase 1 clinical trial to evaluate PTC518 in healthy volunteers. The Phase 1 study includes both single and multiple ascending dosing regimens that will help establish the safety, pharmacology, and dose selection for the Phase 2 study.
A recent study published in “Experimental Brain Research”, a journal of the Nature Group, investigates the relationship between the ability to visually scan and the difficulty of recognizing others’ emotions, in the pre-symptomatic phase of Huntington's disease (preHD). Why is this important?
On October 28th, in an official press release, Prilenia Therapeutics , a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, announced the enrollment of the first patients in the U.S. into PROOF-HD, a global phase 3 clinical trial for Huntington’s Disease (HD).